Market Overview

Jefferies Reiterates Buy Rating, $36 PT on Incyte Corporation Despite PML Case

Share:
Related INCY
Biotech Investors: May 29th Could Be A Big Day
CAR-T Therapy Stocks Hit Hard Following AACR Data
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co. (Seeking Alpha)

In a report published Monday, Jefferies analyst Thomas Wei reiterated a Buy rating and $36.00 price target on Incyte Corporation (NASDAQ: INCY).

In the report, Wei noted, “INCY today disclosed a 75-year old male patient developed PML, a rare brain infection, while taking Jakafi. We still believe that the overall risk-benefit profile of Jakafi is favorable and note that the causal relationship between Jakafi and the PML case is unclear with spontaneous reports of PML in the myelofibrosis literature, and there has been a favorable trend on overall survival seen in the Phase 3 trials.”

Incyte Corporation closed on Friday at $24.84.

Latest Ratings for INCY

DateFirmActionFromTo
Apr 2015JMP SecuritiesMaintainsMarket Outperform
Feb 2015OppenheimerMaintainsOutperform
Feb 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (INCY)

Around the Web, We're Loving...

Get Benzinga's Newsletters